Dystrophin-glycoprotein complex (DGC)

The **dystrophin-glycoprotein complex** is a multiprotein assembly at the sarcolemma (muscle cell membrane) that anchors the intracellular actin cytoskeleton to the extracellular matrix via connections to laminin and other matrix proteins[1][2][3]. The central protein, dystrophin, forms a bridge between cytoskeletal actin and transmembrane dystroglycans, which in turn interact with sarcoglycans, sarcospan, dystrobrevin, syntrophins, and neuronal nitric oxide synthase (nNOS)[1][2][5]. The complex confers mechanical stability to muscle fibers during contraction, serves as a signaling and scaffolding hub for associated proteins, and regulates mechanosensitive ion channels and signaling pathways. Disruption (via mutations in DMD or associated genes) weakens the sarcolemma, causing muscle fragility and degeneration, the primary mechanisms in Duchenne and some limb girdle muscular dystrophies[1][2][3][5][6]. The DGC as a whole is not a classical therapeutic target such as a receptor or enzyme but a structural complex; however, its components, especially dystrophin, are the focus of genetic and molecular therapies for muscular dystrophy[2][3]. The term “dystrophin-glycoprotein complex at the sarcolemma” appropriately describes the location and composition, but as a target, it is too broad—therapeutic efforts focus on specific subunits (e.g., dystrophin). Restoration strategies include gene replacement, exon skipping, and upregulation of homologues like utrophin[3][5]. - This entry is considered “incorrect” as a single therapeutic target because the DGC is a multiprotein complex, not a single molecule or classic drug target. Individual components (e.g., dystrophin, β-dystroglycan) are the more specific and proper targets for therapeutic intervention[2][3][5].

Other names

Dystrophin-associated protein complexDAPCDystrophin-associated glycoprotein complex